CEO Dr. Danyi Wen
Dr. Wen’s research foundation was 12 years at Millennium Pharmaceutical, Biogen-Idec in Boston, MA. In 2007, inspired by the innovation originating from home, she returned back to China as VP of Biology at Shanghai ChemPartner. She founded Shanghai LIDE Biotech in 2011 to drive research and development in personalized precision medicine. She holds a B.S. from the Fourth Military Medical University, an M.S. (M.D. equivalent) from Peking Union Medical University / Chinese Academy of Medical Sciences and an MBA from Suffolk University. She did her post-doc at Harvard Medical School, Brigham & Women's Hospital)
Our executive team in the US and EU work closely with our Chinese operations to ensure our non-China based clients have an immediate resource that can facilitate coordination and communications.
Josh Caggiula, Vice President, Global BD - Europe, APAC
www.linkedin.com/in/jcaggiula
Josh started his career at Johnson & Johnson working across consumer brands in their McNeil Consumer Healthcare business. After several years at a leading digital agency for life sciences, Josh became a senior consultant for a European-based global consultancy where he provided advisory for omnichannel strategies and digital transformation at several multinational pharmaceutical companies. In 2015, Josh became Partner and CMO/CCO for an advanced life sciences IT service provider and the co-founder/CMO of a Conversational AI platform for life sciences called Paro AI.
Josh is looking forward to support and lead LIDE’s expansion into the United States and Europe to bring their range of precision medicine and translational research capabilities to patients around the world.
Liyu Wu, Vice President, Global BD - North America
www.linkedin.com/in/liyuwu
Liyu Wu brings a strong foundation of translational science to LIDE, having spent her PhD and Postdoctoral years investigating cancer biology and cell-signaling mechanisms. Over the past 16 years, Liyu has built a multifaceted career spanning business development, strategic partnerships, product launches, and commercial leadership. Her experience includes key roles at Champions Oncology, WuXi AppTec, and Pharmaron. Most recently, she served as Head of Commercial at Atombeat, overseeing U.S. and European commercialization of the company’s computational drug-discovery platform.
With her combined scientific expertise and commercial acumen, Liyu is committed to driving LIDE’s global oncology collaborations and expanding access to the company’s precision research platforms for partners across translational research and drug development.
Simon Jiang, Vice President, Innovation & Strategy, Head of Scientific Engagement
Dr. Diandong Jiang studied and worked in the United Kingdom for over 20 years and has more than 15 years of research experience in oncology and tumor immunology. He has extensive expertise in pharmacology, translational research, and IND-enabling studies. Dr. Jiang is a recipient of the 2023 Shanghai High-Level Talent Award and the 2024 Shanghai Innovation Award. He has successfully led and completed two innovative biologics IND applications. He obtained his Master’s degree from the University of York, and his PhD from the University of Nottingham.
Loc Van, Executive Director, Program Management
www.linkedin.com/in/locvan
Loc spent the last 10 years helping pharmaceutical and healthcare companies build IT systems and infrastructure to deliver personalized digital experiences to their consumers. He looks forward to helping LIDE expand their technology offering outside of China to deliver personal medicine to patients worldwide.